Clinical Significance of Immunohistochemical Markers of Diffuse Large B-Cell Lymphoma In the Rituximab Era.

被引：0
|
作者：
Hayama, Miyuki [1 ]
Okamoto, Masataka [2 ]
Hagiwara, Yuki [1 ]
Tanae, Ken [1 ]
Kohri, Mika [1 ]
Takahashi, Naoki [1 ]
Yoshino, Tadashi [2 ]
Ohshima, Koichi [2 ]
Niitsu, Nozomi [1 ]
机构：
[1] Saitama Med Univ, Int Med Ctr, Dept Hematol, Hidaka, Japan
[2] ALTSG, Nagoya, Aichi, Japan
来源：
BLOOD | 2010年 / 116卷 / 21期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：752 / 752
页数：1
相关论文
共 50 条
  • [1] CLINICAL SIGNIFICANCE OF BIOMARKERS OF DIFFUSE LARGE B-CELL LYMPHOMA IN THE RITUXIMAB ERA
    Niitsu, N.
    Hayama, M.
    Hagiwara, Y.
    Tanae, K.
    Kohri, M.
    Takahashi, N.
    ANNALS OF ONCOLOGY, 2011, 22 : 154 - 154
  • [2] Prognostic impact of immunohistochemical biomarkers in diffuse large B-cell lymphoma in the rituximab era
    Seki, Ritsuko
    Ohshima, Koichi
    Fujisaki, Tomoaki
    Uike, Naokuni
    Kawano, Fumio
    Gondo, Hisashi
    Makino, Shigeyoshi
    Eto, Tetsuya
    Moriuchi, Yukiyoshi
    Taguchi, Fumihiro
    Kamimura, Tomohiko
    Tsuda, Hiroyuki
    Ogawa, Ryosuke
    Shimoda, Kazuya
    Yamashita, Kiyoshi
    Suzuki, Keiko
    Suzushima, Hitoshi
    Tsukazaki, Kunihiro
    Higuchi, Masakazu
    Utsunomiya, Atae
    Iwahashi, Masahiro
    Imamura, Yutaka
    Tamura, Kazuo
    Suzumiya, Junji
    Yoshida, Minoru
    Abe, Yasunobu
    Matsumoto, Tadashi
    Okamura, Takashi
    CANCER SCIENCE, 2009, 100 (10): : 1842 - 1847
  • [3] Prognostic Significance of EBV Association in Diffuse Large B-Cell Lymphoma in the Rituximab Era
    Niitsu, Nozomi
    Takahashi, Naoki
    Yoshino, Tadashi
    Okamoto, Masataka
    Nakamura, Shigeo
    BLOOD, 2015, 126 (23)
  • [4] Prognostication of diffuse large B-cell lymphoma in the rituximab era
    Ninan, Mary J.
    Wadhwa, Punit D.
    Gupta, Pankaj
    LEUKEMIA & LYMPHOMA, 2011, 52 (03) : 360 - 373
  • [5] Outcome of diffuse large B cell lymphoma in the VA system: The rituximab era.
    Komrokji, Rami S.
    Maraboyina, Sanjay
    Haddad, Rami Y.
    Nahleh, Zeina A.
    Safa, Malek M.
    BLOOD, 2006, 108 (11) : 265B - 265B
  • [6] Outcomes of Cardiac Diffuse Large B-Cell Lymphoma in the Rituximab Era
    Al-Juhaishi, Taha
    Abu Zeinah, Ghaith
    Al-Kindi, Sadeer
    BLOOD, 2020, 136
  • [7] Primary breast diffuse large B-cell lymphoma in the era of rituximab
    Zhang, Na
    Cao, Caineng
    Zhu, Yuan
    Liu, Peng
    Liu, Luying
    Lu, Ke
    Luo, Jialin
    Zhou, Ning
    ONCOTARGETS AND THERAPY, 2016, 9 : 6093 - 6097
  • [8] Prognostic factors for diffuse large B-cell lymphoma: clinical and biological factors in the rituximab era
    Liang, Xiping
    Hu, Renzhi
    Li, Qiying
    Wang, Chaoyu
    Liu, Yao
    EXPERIMENTAL HEMATOLOGY, 2023, 122 : 1 - 9
  • [9] Prognostic significance of immunohistochemical classification of diffuse large B-cell lymphoma
    Alacacioglu, Inci
    Ozcan, Mehmet Ali
    Ozkal, Sermin
    Piskin, Ozden
    Turgut, Nurhilal
    Demirkan, Fatih
    Ozsan, Guner Hayri
    Kargi, Aydanur
    Undar, Bulent
    HEMATOLOGY, 2009, 14 (02) : 84 - 89
  • [10] Serum B-cell activating factor (BAFF) in diffuse large B-cell lymphoma: Its prognostic significance in the rituximab era
    Kim, Seok Jin
    Sung, Hwa Jung
    Choi, Chul Won
    Kim, In Sun
    Kim, Byung Soo
    Yoon, Soo-Young
    Won, Jong-Ho
    Kim, Jun Suk
    BLOOD, 2007, 110 (11) : 470A - 471A
12345